Literature DB >> 24246609

Postoperative infections after cytoreductive surgery and HIPEC for peritoneal carcinomatosis: proposal and results from a prospective protocol study of prevention, surveillance and treatment.

M Valle1, O Federici2, F Carboni2, L Toma3, M T Gallo4, G Prignano4, D Giannarelli5, L Cenci2, A Garofalo2.   

Abstract

The incidence of infectious complications due to several contributory causes is particularly elevated and life-threatening in patients undergoing peritonectomy and HIPEC procedure for peritoneal carcinomatosis. Following a previous experience, we started a prospective protocol study of preoperative screening, perioperative prophylaxis and postoperative surveillance and treatment. A total of 111 patients with peritoneal carcinomatosis of various origin underwent CRS with HIPEC between April 2004 and December 2012. The group was divided into a pilot group of 30 patients (04/04 to 05/08) and a main group of 81 patients (06/08 to 12/12). Overall postoperative morbidity rate was 44%, with 35.8% of symptomatic infections. No post-operative mortality was observed. Microorganisms were isolated in 24 patients (80.0%) in the first group and 54 (66.7%) in the second. They were symptomatic in 18 cases (75.0%) and 25 (46.3%) cases respectively. In addition, 7 invasive candidosis were recorded (25.9%). Colon resection (P = 0.01) and duration of surgery (P = 0.0008) were associated with infection at logistic regression model. Concerning symptomatic infections, only Infection Risk Index (P = 0.009) showed significance at multivariate analysis. Despite a significant incidence of infectious complications, establishment of a prevention, surveillance and treatment protocol lead to a zero mortality rate in the observed patients of our experience. Owing to the obtained results, we suggest the use of a standardized protocol for the prevention, monitoring and treatment in all patients enrolled for cytoreductive surgery and HIPEC.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  HIPEC; Infection; Peritonectomy

Mesh:

Year:  2013        PMID: 24246609     DOI: 10.1016/j.ejso.2013.10.015

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  13 in total

1.  Does Intraoperative Systematic Bacterial Sampling During Complete Cytoreductive Surgery (CRS) with Hyperthermic Intraoperative Peritoneal Chemotherapy (HIPEC) Influence Postoperative Treatment? A New Predictive Factor for Postoperative Abdominal Infectious Complications.

Authors:  Marie Dazza; Lilian Schwarz; Julien Coget; Noelle Frebourg; Gregory Wood; Emmanuel Huet; Valérie Bridoux; Benoit Veber; Jean-Jacques Tuech
Journal:  World J Surg       Date:  2016-12       Impact factor: 3.352

2.  Benchmarking Perioperative Outcomes of Cytoreductive Surgery for Cancer: Implications for Quality Measurement.

Authors:  Jason B Liu; Darryl Schuitevoerder; Charles C Vining; Yaniv Berger; Kiran K Turaga; Oliver S Eng
Journal:  Ann Surg Oncol       Date:  2020-07-29       Impact factor: 5.344

3.  Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal metastasis of non-primary origin.

Authors:  Fabio Carboni; Orietta Federici; Settimio Zazza; Francesco Corona; Fanny Massimi; Isabella Sperduti; Mario Valle
Journal:  Langenbecks Arch Surg       Date:  2021-10-23       Impact factor: 3.445

Review 4.  Imaging of pre- and post-cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pediatric intraperitoneal malignancy.

Authors:  Nathan C Hull; Candace F Granberg; Patricio C Gargollo; Paul G Thacker
Journal:  Pediatr Radiol       Date:  2022-10-07

Review 5.  Multimodality treatment strategies have changed prognosis of peritoneal metastases.

Authors:  Corneliu Lungoci; Aurel Ion Mironiuc; Valentin Muntean; Traian Oniu; Hubert Leebmann; Max Mayr; Pompiliu Piso
Journal:  World J Gastrointest Oncol       Date:  2016-01-15

6.  Increased RHAMM expression relates to ovarian cancer progression.

Authors:  Stephanie T Buttermore; Mitchel S Hoffman; Ambuj Kumar; Anne Champeaux; Santo V Nicosia; Patricia A Kruk
Journal:  J Ovarian Res       Date:  2017-09-27       Impact factor: 4.234

7.  Increased Plasma Levels of Danger-Associated Molecular Patterns Are Associated With Immune Suppression and Postoperative Infections in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Authors:  Guus P Leijte; Hettie Custers; Jelle Gerretsen; Amon Heijne; Johannes Roth; Thomas Vogl; Gert J Scheffer; Peter Pickkers; Matthijs Kox
Journal:  Front Immunol       Date:  2018-04-05       Impact factor: 7.561

8.  Prognostic Factors Influencing Infectious Complications after Cytoreductive Surgery and HIPEC: Results from a Tertiary Referral Center.

Authors:  Maurizio Cardi; Simone Sibio; Francesco Di Marzo; Francesco Lefoche; Claudia d'Agostino; Giovanni Battista Fonsi; Giuseppe La Torre; Ludovica Carbonari; Paolo Sammartino
Journal:  Gastroenterol Res Pract       Date:  2019-05-02       Impact factor: 2.260

9.  Perioperative management and postoperative outcome of patients undergoing cytoreduction surgery with hyperthermic intraperitoneal chemotherapy.

Authors:  Hamed Elgendy; Hanaa Nafady-Hego; Hanan M Abd Elmoneim; Talha Youssef; Abdulaziz Alzahrani
Journal:  Indian J Anaesth       Date:  2019-10-10

10.  Analysis of Bacterial and Fungal Infections after Cytoreduction Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Observational Single-Centre Study.

Authors:  Talat A M Albukhari; Hanaa Nafady-Hego; Hamed Elgendy; Hanan M Abd Elmoneim; Asmaa Nafady; Abdulaziz M Alzahrani
Journal:  Int J Microbiol       Date:  2019-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.